amotosalen has been researched along with methylene blue in 10 studies
| Studies (amotosalen) | Trials (amotosalen) | Recent Studies (post-2010) (amotosalen) | Studies (methylene blue) | Trials (methylene blue) | Recent Studies (post-2010) (methylene blue) |
|---|---|---|---|---|---|
| 179 | 18 | 103 | 11,067 | 394 | 4,258 |
| Protein | Taxonomy | amotosalen (IC50) | methylene blue (IC50) |
|---|---|---|---|
| Chain E, Fibrin beta chain | Homo sapiens (human) | 9.253 | |
| integrase, partial | Human immunodeficiency virus 1 | 1.958 | |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | 1.958 | |
| Apoptotic peptidase activating factor 1 | Homo sapiens (human) | 15.5 | |
| neutrophil cytosol factor 1 | Homo sapiens (human) | 0.39 | |
| caspase-9 isoform alpha precursor | Homo sapiens (human) | 17 | |
| caspase-3 isoform a preproprotein | Homo sapiens (human) | 17 | |
| Glutathione reductase | Plasmodium falciparum 3D7 | 6.4 | |
| Amyloid-beta precursor protein | Homo sapiens (human) | 0.5 | |
| Microtubule-associated protein tau | Homo sapiens (human) | 2.2333 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.5 | |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | 0.07 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.5 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allain, JP; Bianco, C; Blajchman, MA; Brecher, ME; Busch, M; Leiby, D; Lin, L; Stramer, S | 1 |
| Gatehouse, D; Kirkland, D; Speit, G; Tice, RR | 1 |
| Calomme, G; Chatelain, B; Debry, C; Dubuc, E; Goffaux, M; Hsu, J; Lin, L; Osselaer, JC; Pineau, J; Rheinschmidt, M; Vandendaele, MC | 1 |
| McCullough, J | 1 |
| Cid, J; Claparols, M; Magallon, O; Martínez, N; Ortiz, P; Palomo, M; Pla, RP; Puig, L; Ramiro, L | 1 |
| Rock, G | 1 |
| Cauet, A; Martinaud, C; Sailliol, A | 1 |
| Müller, TH; Seltsam, A | 1 |
| Backholer, L; Cardigan, R; Cookson, P; Proffitt, S; Wiltshire, M | 1 |
| Bazhenov, AI; Bogdanova, AS; Borovkova, NV; Bulanov, AY; Chirkova, KS; Dolzhikova, IV; Dombrovskiy, EA; Drozdova, NE; Ganchin, VV; Gintsburg, AL; Godkov, MA; Kamalova, AR; Kostin, AI; Ladygina, EA; Logunov, DY; Lundgren, MN; Petrikov, SS; Shcheblyakov, DV; Shustov, VV; Volkov, SE | 1 |
5 review(s) available for amotosalen and methylene blue
| Article | Year |
|---|---|
Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
Topics: Anti-Infective Agents; Blood; Blood Banks; Blood Component Transfusion; Blood Transfusion; Blood-Borne Pathogens; Communicable Disease Control; Detergents; Furocoumarins; Humans; Infections; Methylene Blue; Photosensitizing Agents; Polyamines; Prions; Riboflavin; Risk; Solvents; Time Factors; Transfusion Reaction; Ultraviolet Rays | 2005 |
Pathogen inactivation: a new paradigm for preventing transfusion-transmitted infections.
Topics: Alkylating Agents; Anti-Infective Agents; Blood Banks; Blood Transfusion; Blood-Borne Pathogens; Communicable Disease Control; Detergents; Furocoumarins; Humans; Methylene Blue; Photosensitizing Agents; Randomized Controlled Trials as Topic; Riboflavin; Transfusion Reaction | 2007 |
A comparison of methods of pathogen inactivation of FFP.
Topics: Animals; Blood Banking; Blood Proteins; Detergents; Disinfection; Enzyme Inhibitors; Furocoumarins; Humans; Methylene Blue; Plasma | 2011 |
[Therapeutic plasmas available worldwide].
Topics: Blood Component Transfusion; Blood Donors; Blood Preservation; Blood Safety; Commerce; Detergents; Disasters; France; Freeze Drying; Furocoumarins; Global Health; Health Services Needs and Demand; Hemorrhage; Humans; Leukocyte Reduction Procedures; Methylene Blue; Microbial Viability; Photosensitizing Agents; Plasma; Riboflavin; Solvents; Ultraviolet Rays; Warfare; World Health Organization | 2013 |
Update on the use of pathogen-reduced human plasma and platelet concentrates.
Topics: Blood Cells; Blood Component Transfusion; Blood Safety; Blood-Borne Pathogens; Clinical Trials as Topic; Cost-Benefit Analysis; Detergents; Double-Blind Method; Furocoumarins; Humans; Intercalating Agents; Methylene Blue; Multicenter Studies as Topic; Photosensitizing Agents; Plasma; Platelet Transfusion; Riboflavin; Risk Assessment; Solvents; Ultraviolet Rays; Virus Inactivation | 2013 |
5 other study(ies) available for amotosalen and methylene blue
| Article | Year |
|---|---|
The pathogen reduction treatment of platelets with S-59 HCl (Amotosalen) plus ultraviolet A light: genotoxicity profile and hazard assessment.
Topics: Animals; Biotransformation; Blood Platelets; CHO Cells; Comet Assay; Cricetinae; Cricetulus; Decontamination; DNA Damage; Escherichia coli; Furocoumarins; Genes, p53; Methylene Blue; Mice; Mice, Transgenic; Micronucleus Tests; Rats; Rats, Inbred F344; Salmonella; Ultraviolet Rays | 2007 |
Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen.
Topics: Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Furocoumarins; Humans; Light; Methylene Blue; Photochemistry; Plasma; Ultraviolet Rays; Virus Inactivation | 2008 |
Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments.
Topics: Blood Coagulation Factors; Blood Proteins; Blood-Borne Pathogens; Fibrinogen; Furocoumarins; Humans; Light; Methylene Blue; Photochemistry; Plasma; Ultraviolet Rays; Virus Inactivation; von Willebrand Factor | 2008 |
Paired comparison of methylene blue- and amotosalen-treated plasma and cryoprecipitate.
Topics: Blood Coagulation Factors; Fibrinogen; Furocoumarins; Humans; Matched-Pair Analysis; Methylene Blue; Photosensitizing Agents; Plasma; Thrombelastography; Thrombin; Virus Inactivation | 2016 |
Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma.
Topics: Antibodies, Neutralizing; Blood Safety; Blood-Borne Pathogens; COVID-19; COVID-19 Serotherapy; Furocoumarins; Humans; Immunization, Passive; Methylene Blue; Plasma; Riboflavin; SARS-CoV-2 | 2021 |